Abstract
Metformin functions through a gut microbiome–bile acid–farnesoid X receptor axis to lower glucose in type 2 diabetes, revealing a new therapeutic target in this disease.
Original language | English (US) |
---|---|
Pages (from-to) | 1789-1790 |
Number of pages | 2 |
Journal | Nature medicine |
Volume | 24 |
Issue number | 12 |
DOIs |
|
State | Published - Dec 1 2018 |
All Science Journal Classification (ASJC) codes
- Biochemistry, Genetics and Molecular Biology(all)